Skip to main content

Mosapramine









Mosapramine


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search




































































Mosapramine
Mosapramine.svg
Mosapramine-xtal-1993-ball-and-stick.png
Clinical data
Trade names Cremin (クレミン, JP)

AHFS/Drugs.com
International Drug Names
Routes of
administration

Oral (tablets, oral solution)
ATC code

  • N05AX10 (WHO)
Legal status
Legal status

  • Rx-only (JP)


Identifiers
CAS Number

  • 89419-40-9 ☑Y

PubChem CID
  • 4257
ChemSpider
  • 4107
UNII
  • 04UZQ7O9SJ
KEGG

  • D08235 ☑Y
Chemical and physical data
Formula
C28H35ClN4O
Molar mass 479.057 g/mol
3D model (JSmol)
  • Interactive image

.mw-parser-output .nobold{font-weight:normal}
  (verify)

Mosapramine (Cremin) is an atypical antipsychotic used in Japan.[1] It is a potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors,[2] and with moderate affinity for the 5-HT2 receptors.[3]



See also[edit]



  • Carpipramine

  • Clocapramine

  • Imidazopyridine



References[edit]





  1. ^ Takahashi N, Terao T, Oga T, Okada M. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology. 1999;39(2):81-5. .mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}
    PMID 10072664



  2. ^ Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T. The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors. Nippon Yakurigaku Zasshi. (Japanese) 1996 May;107(5):247-53.
    PMID 8690306



  3. ^ Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K. Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. Neuropsychopharmacology. 1995 Feb;12(1):57-64. doi:10.1016/0893-133X(94)00064-7
    PMID 7766287

















Retrieved from "https://en.wikipedia.org/w/index.php?title=Mosapramine&oldid=795647701"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"1.200","walltime":"1.465","ppvisitednodes":{"value":5405,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":614706,"limit":2097152},"templateargumentsize":{"value":204412,"limit":2097152},"expansiondepth":{"value":15,"limit":40},"expensivefunctioncount":{"value":1,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":7058,"limit":5000000},"entityaccesscount":{"value":1,"limit":400},"timingprofile":["100.00% 762.302 1 -total"," 54.18% 412.996 1 Template:Drugbox"," 36.05% 274.824 1 Template:Infobox"," 28.17% 214.747 28 Template:Navbox"," 25.21% 192.183 2 Template:Navboxes"," 19.90% 151.724 1 Template:Reflist"," 10.72% 81.691 16 Template:Unbulleted_list"," 10.46% 79.753 3 Template:PMID"," 9.91% 75.510 3 Template:Catalog_lookup_link"," 8.12% 61.891 1 Template:Serotonin_receptor_modulators"]},"scribunto":{"limitreport-timeusage":{"value":"0.221","limit":"10.000"},"limitreport-memusage":{"value":3536892,"limit":52428800}},"cachereport":{"origin":"mw1285","timestamp":"20181216042814","ttl":1900800,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":158,"wgHostname":"mw1269"});});

Popular posts from this blog

Full-time equivalent

さくらももこ

13 indicted, 8 arrested in Calif. drug cartel investigation